Buy Ratings On Merck (MRK) & Tcr2 Therapeutics (TCRR)
b'Merck & Co. (MRK) is testing a new prostate cancer drug and successful drug studies to fight liver cancer and melanoma. Tcr2 Therapeutics (TCRR) is turning focus to ovarian cancer and has a large addressable market. "Merck has dominance in the oncology space with KEYTRUDA. There has been a flight to quality stocks like MRK in a rising interest rate environment. Tcr2 Therapeutics works on the cell therapy side," says Mara Goldstein.'